TUMOR MARKERS AND SIGNATURES

Genome-wide association studies of toxicity to oxaliplatin and fluoropyrimidine chemotherapy with or without cetuximab in 1800 patients with advanced colorectal cancer

Katie Watts1 | Christopher Wills1 | Ayman Madi2 | Claire Palles3 | Timothy S. Maughan4 | Richard Kaplan5 | Nada A. Al-Tassan6 | Rachel Kerr7 | David Kerr8 | Victoria Gray1 | Claire Palles3 | Richard S. Houlston9 | Valentina Escott-Price10 | Jeremy P. Cheadle1

1Division of Cancer and Genetics, School of Medicine, Cardiff University, Cardiff, UK
2The Clatterbridge Cancer Centre NHS Foundation Trust, Bebington, UK
3Institute of Cancer and Genomic Sciences, Institute of Biomedical Research, University of Birmingham, Birmingham, UK
4CRUK/MRC Oxford Institute for Radiation Oncology, University of Oxford, Oxford, UK
5MRC Clinical Trials Unit, University College of London, London, UK
6Department of Genetics, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia
7Department of Oncology, University of Oxford, Oxford, UK
8Nuffield Department of Clinical Laboratory Sciences, University of Oxford, John Radcliffe Hospital, Oxford, UK
9Division of Genetics and Epidemiology, The Institute of Cancer Research, London, UK
10Institute of Psychological Medicine and Clinical Neurosciences, School of Medicine, Cardiff University, Cardiff, UK

Correspondence
Jeremy P. Cheadle, Division of Cancer and Genetics, School of Medicine, Cardiff University, Heath Park, Cardiff, CF14 4XN, UK.
Email: cheadlejp@cardiff.ac.uk

Funding information
Cancer Research UK, Grant/Award Number: C1298/A8362; Cardiff University School of Medicine.

Abstract
Chemotherapies administered at normal therapeutic dosages can cause significant side-effects and may result in early treatment discontinuation. Inter-individual variation in toxicity highlights the need for biomarkers to personalise treatment. We sought to identify such biomarkers by conducting 40 genome-wide association studies, together with gene and gene set analyses, for any toxicity and 10 individual toxicities in 1800 patients with advanced colorectal cancer treated with oxaliplatin and fluoropyrimidine chemotherapy ± cetuximab from the MRC COIN and COIN-B trials (385 patients received FOLFOX, 360 FOLFOX + cetuximab, 707 XELOX and 348 XELOX + cetuximab). Single nucleotide polymorphisms (SNPs), genes and gene sets that reached genome-wide or suggestive significance were validated in independent patient groups. We found that MROH5 was significantly associated with neutropenia in MAGMA gene analyses in patients treated with XELOX ($P = 6.6 \times 10^{-7}$) and was independently validated in those receiving XELOX + cetuximab; pooled $P = 3.7 \times 10^{-7}$, rs13260246 at 8q21.13 was significantly associated with vomiting in patients treated with XELOX (odds ratio = 5.0, 95% confidence interval = 3.0-8.3, $P = 9.8 \times 10^{-10}$) but was not independently replicated. SNPs at 139 loci had suggestive associations for toxicities and lead SNPs at five of these were independently validated (rs6030266 with diarrhoea, rs1546161 with hand-foot syndrome, rs9601722 with neutropenia, rs13413764 with lethargy and rs4600090 with nausea; all with pooled Ps < 5.0 \times 10^{-6}). In conclusion, the association of MROH5 with neutropenia and five other putative biomarkers warrant further investigation for their potential clinical utility. Despite our comprehensive genome-wide analyses of large, well-characterised, clinical trials, we found a lack of common variants with modest effect sizes associated with toxicities.

Abbreviations:
CRC, colorectal cancer; CTCAE, Common Terminology Criteria for Adverse Events; eQTL, expression quantitative trait loci; GWAS, genome-wide association study; QUASAR2, Quick and Simple and Reliable Trial; SNP, single nucleotide polymorphism; sQTL, splicing quantitative trait loci.

Received: 11 March 2021 Revised: 12 May 2021 Accepted: 8 June 2021
DOI: 10.1002/ijc.33739

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
© 2021 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC.
1 | INTRODUCTION

Many patients diagnosed with colorectal cancer (CRC) receive chemotherapy either as part of their treatment for curative disease or to extend survival. Most chemotherapeutic agents are associated with significant side effects even if administered at normal therapeutic dosages.

The combination of fluoropyrimidine and oxaliplatin is a common first-line treatment for many cancers including CRC. XELOX (XEL = capecitabine, OX = oxaliplatin) is an oral fluoropyrimidine with similar efficacy to FOLFOX (FOL = folinic acid, F = fluorouracil, OX = oxaliplatin) but with differing toxicity profiles. Whereas XELOX often causes gastrointestinal symptoms and hand-foot syndrome, FOLFOX tends to affect immunity. Cetuximab, a monoclonal antibody directed against the epidermal growth factor receptor, is also used in the treatment of CRC and often causes skin rashes.

Some toxicities have short-term acute effects whereas others remain after treatment has stopped. Toxicity adversely affects a patient's quality of life and can be life threatening. Drug toxicity may result in treatment discontinuation or dose reduction, thus significantly affecting the prospects of a cure.

Since there is significant inter-individual variation in chemotherapy-related toxicity, the identification of predictive biomarkers is highly desirable to personalise therapy. The role of inherited genetic factors is increasingly being recognised to influence patient chemotherapy-related toxicity. Notably, rare variants in the gene encoding dihydropyrimidine dehydrogenase (DPYD) are well established to be associated with severe toxicities to 5-fluorouracil (5-FU). While the role of common genetic variation is less clear, we and others have shown that common variants in DPYD also appear to affect the toxicity. To date, most studies have sought to identify inherited predictive biomarkers using candidate gene and variant-based analyses, based on preconceptions as to probable biology and using small cohorts of patients with no independent validation. To address such limitations, we have analysed genome-wide association study (GWAS) data on 1800 patients with advanced CRC treated with oxaliplatin and fluoropyrimidine chemotherapy ± cetuximab with replication in independent patient groups.

2 | MATERIALS AND METHODS

2.1 | Patients and samples

In total, 2671 patients with metastatic or locally advanced colorectal adenocarcinoma were recruited into the MRC clinical trials COIN (ISRCTN27286448) and COIN-B (ISRCTN3837568). None of the patients had previously received chemotherapy for advanced disease. COIN patients were randomised 1:1:1 to receive continuous oxaliplatin and fluoropyrimidine chemotherapy (Arm A, n = 815), continuous chemotherapy with cetuximab (Arm B, n = 815) or intermittent chemotherapy (Arm C, n = 815). COIN-B patients were randomised 1:1 to receive intermittent chemotherapy and cetuximab (Arm D, n = 112) or intermittent chemotherapy and continuous cetuximab (Arm E, n = 114) (Figure 1). For the first 12 weeks, treatments were identical in all patients apart from the choice of fluoropyrimidine (n = 1068, 40% received FOLFOX and n = 1603, 60% received XELOX) together with the randomisation of ± cetuximab (n = 1041, 39% received cetuximab) (Figure 1). Overall, patients had a mean age at randomisation of 62 years (range, 18-87) and 36% were female. Blood DNA samples were prepared from 2244 of the 2671 patients.

2.2 | Clinical end points assessed and power considerations

Assessment of toxicity was performed at 12 weeks, since at this point patients from all trial arms received identical levels of chemotherapy (choice of XELOX or FOLFOX) with or without cetuximab. This time point was also prior to any interruption to treatment for the intermittent therapy arms.

The primary end point assessed was any toxicity graded by critical adverse events as per the Common Terminology Criteria for Adverse Events (CTCAE version 4.0) with the highest grade noted within the first 12 weeks of treatment (assessed at 6 and 12 weeks). Secondary end points were individual toxicities (diarrhoea, neutropenic sepsis,
peripheral neuropathy, hand-foot syndrome, neutropenia, lethargy, stomatitis, nausea, vomiting and rash) graded by CTCAE score with the highest grade noted within the first 12 weeks of treatment (assessed at 6 and 12 weeks). Patients with toxicities graded 2 to 5 were compared against those graded 0 to 1.

Logistic regression models were used to determine if the chemotherapy regimen and cetuximab administration affected toxicity occurrence. Power to detect the toxicity effect sizes was calculated using the genpwr package in R,19 based upon 70% power, a standard GWAS significance of $P = 5.0 \times 10^{-8}$ and single nucleotide polymorphisms (SNPs) with minor allele frequencies (MAFs) of 0.20.

### 2.3 | Genotyping

In all, 2244 patients were genotyped using Affymetrix Axiom Arrays according to the manufacturer’s recommendations (Affymetrix, Santa Clara, CA) at the King Faisal Specialist Hospital and Research Center, Saudi Arabia (under IRB approval 2110033).20 After quality control, SNP genotypes were available for 1950 patients.20 For 150 of the 1950 patients, no data on toxicity had been collected at 12 weeks and these were excluded leaving 1800 for analysis (Figure 1). Additional imputation was performed for an 800 Mb region surrounding MROH5 (to provide better SNP coverage) using the Phase...

### 2.4 | Initial GWAS analyses

Patients from COIN and COIN-B were analysed for associated genetic biomarkers after segregating by chemotherapy regimen and cetuximab status; 385 patients had FOLFOX, 360 had FOLFOX + cetuximab, 707 had XELOX and 348 had XELOX + cetuximab (Figure 1). Genome-wide association analyses were run under a univariate additive model in Plink v1.921 and results were plotted in R studio using qqman.22 A logistic regression method was chosen. SNPs that showed an association at $P < 1.0 \times 10^{-5}$ (suggestive of significance) were selected for independent validation. Results are reported in accordance with STREGA guidelines.

### 2.5 | MAGMA gene and gene set analyses

MAGMA23 was used for gene and gene set analyses using data files from the NCBI 37.3 gene definitions and ~8500 predefined gene sets. Gene analyses were run under a snpwise univariate model imposing a Bonferroni corrected significance threshold of $P = 2.5 \times 10^{-6}$ (Figure 1). Gene set analyses were run under both competitive and...
self-contained models with a corrected significance threshold of $P = 5.8 \times 10^{-6}$ (Figure 1).

### 2.6 Validation analyses

SNPs, genes and gene sets that reached genome-wide or suggestive significance in the GWAS analyses were independently validated in: (a) the COIN and COIN-B group with the same chemotherapy regimen but alternative cetuximab status and (b) the COIN and COIN-B group with the alternative chemotherapy regimen but with the same cetuximab status (Figure 1). For example, a SNP identified from the group receiving FOLFOX was validated in those receiving FOLFOX + cetuximab and in those receiving XELOX. A SNP identified from the group receiving XELOX was validated in those receiving XELOX + cetuximab and in those receiving FOLFOX. A SNP identified from the group receiving FOLFOX + cetuximab was validated in those in receiving FOLFOX and those receiving XELOX + cetuximab. A SNP identified from the group receiving XELOX + cetuximab was validated in those in receiving XELOX and those receiving FOLFOX + cetuximab (Figure 1). We considered a nominally significant threshold of $P < .05$ as evidence for validations. We had >85% power to detect our initially observed odds ratios for each validation subgroup.

Because rs13260246 reached genome-wide significance for vomiting in patients treated with XELOX, we also sought validation for this biomarker using data from 927 patients enrolled in the Quick and Simple and Reliable trial (QUASAR2). This was an open-label randomised Phase 3 clinical trial of capcitabine or capcitabine plus bevacizumab in patients with Stage II or III CRCs. Patients were genotyped using the Illumina genome-wide SNP panels (Human Hap 370, Human Hap 610 or Human Omni 2.5). Imputation was performed using IMPUTE2 with 1000 genomes as reference. The INFO score for rs13260246 was 0.96. Vomiting was graded using the CTCAE scale and patients with grades 2 to 5 (22%) were compared to those with grades 0 to 1.

### 2.7 Bioinformatic analyses

The Genotype-Tissue Expression project database was used to identify expression quantitative trait loci (eQTLs) and splicing quantitative trait loci (sQTLs) for relevant SNPs (https://gtexportal.org/home). Significance for tissue association was set at $P < 1.0 \times 10^{-3}$ (ie, Bonferroni correction for 49 tissues [0.05/49]). Fine-mapping was used for SNPs at validated loci; conditional regression was first used to identify the number of causal variants and fine-mapping was then run using PAINTOR, which employs a Bayesian permutation method incorporating ENCODE and FANTOM5 functional annotations. Credible sets of causal SNPs were assembled for 95% coverage.

### 3 RESULTS

There were significant differences in the incidences of toxicities associated with different chemotherapy regimens and cetuximab administration in COIN and COIN-B (Table 1; Supplementary Table 1). Notably, patients treated with FOLFOX had a significantly higher incidence of neutropenic sepsis, neutropenia and stomatitis, those with

| Table 1 | Patients with grades 2 to 5 CTCAE toxicities at 12 weeks |
|---------|--------------------------------------------------------|
|         | FOLFOX treated                                        | XELOX treated                                        |
|         | n = 385 (%)                                            | + cetuximab n = 360 (%)                              | n = 707 (%)                                            | + cetuximab n = 348 (%)                              |
| Any toxicity | 237 (61)                                             | 275 (76)                                            | 430 (61)                                             | 226 (65)                                            |
| Individual toxicities |                                      |                                                     |                                                      |                                                     |
| Diarrhoea          | 78 (20)                                               | 109 (30)                                            | 165 (23)                                             | 123 (35)                                            |
| Neutropenic sepsis | 24 (8)                                                 | 39 (16)                                             | 5 (0.7)                                              | 1 (0.3)                                              |
| Peripheral neuropathy | 43 (11)                                               | 30 (8)                                              | 110 (16)                                             | 44 (13)                                              |
| Hand-foot syndrome | 9 (2)                                                  | 56 (16)                                             | 53 (8)                                               | 56 (16)                                              |
| Neutropenia         | 100 (26)                                               | 119 (33)                                            | 36 (5)                                               | 6 (2)                                                |
| Lethargy           | 130 (34)                                               | 126 (35)                                            | 258 (36)                                             | 103 (30)                                             |
| Stomatitis          | 48 (12)                                                | 102 (28)                                            | 32 (5)                                               | 29 (8)                                               |
| Nausea              | 41 (11)                                                | 47 (13)                                             | 142 (20)                                             | 68 (20)                                              |
| Vomiting            | 25 (6)                                                 | 34 (9)                                              | 87 (12)                                              | 35 (10)                                              |
| Rash                | 5 (1)                                                  | 196 (54)                                            | 11 (2)                                               | 166 (48)                                             |

Notes: Percentage of patients in parentheses. We had 70% power to detect a mean OR of 4.3 (range, 3-6) for any toxicity and 5.9 (2-39) for individual toxicities (Supplementary Table 3). For neutropenic sepsis in patients treated with XELOX and XELOX + cetuximab, neutropenia in patients treated with XELOX + cetuximab and rash in patients treated with FOLFOX, we had insufficient power to perform the genome-wide association studies (GWASs); therefore, in total, we conducted 40 GWASs.
XELOX had a higher incidence of nausea and those with cetuximab had a higher incidence of skin rash, hand-foot syndrome and diarrhoea (Table 1). In view of this, patients were analysed for associations with genetic biomarkers after segregation by chemotherapy treatment and cetuximab status (Figure 1). There were no clinicopathological differences between these treatment groups (Supplementary Table 2).

In total, 4 million SNPs were analysed for a relationship with any toxicity and 10 individual toxicities in each of the four patient groups. Q-Q plots of observed vs expected $\chi^2$-test statistics showed no evidence for an inflation of test statistics for all 40 GWAS’s performed ($\lambda$ range, 0.99-1.02) (Supplementary Figure 1). We had 70% power to detect a mean OR of 4.3 (range, 3-6) for any toxicity and 5.9 (2-39) for individual toxicities (Supplementary Table 3).

### 3.1 | Relationship between SNP genotype and any toxicity

No SNPs were associated with any toxicity at genome-wide significant levels ($P < 5.0 \times 10^{-8}$). SNPs at 27 loci were associated at suggestive levels ($P < 1.0 \times 10^{-5}$) (5 with FOLFOX, 8 with FOLFOX + cetuximab, 7 with XELOX and 7 with XELOX + cetuximab) (Figure 2); however, no lead SNPs were independently validated in COIN and COIN-B patients treated with the same chemotherapy regimen but alternative cetuximab status, or alternative chemotherapy regimen but with the same cetuximab status, despite having >85% power (Supplementary Table 4).

### 3.2 | Relationship between SNP genotype and individual toxicity

#### 3.2.1 | Vomiting

rs13260246 at 8q21.3 was significantly associated with vomiting in patients treated with XELOX (odds ratio [OR] = 5.0, 95% confidence intervals [CIs] = 3.0-8.3, $P = 9.8 \times 10^{-10}$; Figure 3). However, the association was not validated in COIN and COIN-B patients treated with XELOX + cetuximab ($P = .72$), nor in those receiving FOLFOX ($P = .35$), with >90% power (Supplementary Table 5). We also failed to validate the association for rs13260246 with vomiting in the QUASAR2 trial of capcitabine alone vs capcitabine + bevacizumab for Stage II and III CRC, regardless of treatment arm studied (with >99% power) (Supplementary Table 5). rs13260246 was an eQTL for SLC26A7 and five other genes (Supplementary Figure 2). SNPs at 15 loci had suggestive associations with vomiting but none were independently validated.

#### 3.2.2 | Diarrhoea

SNPs at 21 loci had suggestive associations with diarrhoea (Supplementary Figure 3); however, only rs6030266 at 20q13.12 in patients treated with XELOX + cetuximab (OR = 0.4, 95% CI = 0.28-0.58, $P = 5.7 \times 10^{-7}$) was validated in patients receiving FOLFOX + cetuximab (OR = 0.7, 95% CI = 0.5-0.9, $P = 3.6 \times 10^{-3}$); pooled

---

**Figure 2** Manhattan plots of the relationship between single nucleotide polymorphism (SNP) genotype and any toxicity. Patients treated with (A) FOLFOX (n = 385), (B) FOLFOX + cetuximab (n = 360), (C) XELOX (n = 707) and (D) XELOX + cetuximab (n = 348). The red line indicates a genome-wide significance threshold of $P = 5.0 \times 10^{-8}$ and the blue line indicates a suggestive significance threshold of $P = 1.0 \times 10^{-5}$ [Color figure can be viewed at wileyonlinelibrary.com]
3.2.3 | Hand-foot syndrome

SNPs at 13 loci had suggestive associations with hand-foot syndrome (Supplementary Figure 3). Only rs1546161 at 1q21.2 in patients treated with FOLFOX (OR = 17.8, 95% CI = 5.1-62.0, P = 5.9 × 10⁻⁶) was validated in those receiving XELOX (OR = 1.7, 95% CI = 1.1-2.9, P = 3.6 × 10⁻²); pooled P = 2.5 × 10⁻⁶ (Table 2). rs1546161 maps to B-cell lymphoma 9 (BCL9) and was an eQTL for GJA5 (Supplementary Figure 4).

3.2.4 | Neutropenia

SNPs at 13 loci had suggestive associations with neutropenia (Supplementary Figure 3). Only rs9601722 at 13q31.1 in patients treated with FOLFOX + cetuximab (OR = 3.4, 95% CI = 2.0-5.7, P = 5.2 × 10⁻⁶) was independently validated in those receiving FOLFOX (OR = 1.7, 95% CI = 1.1-2.9, P = 3.6 × 10⁻²); pooled P = 3.0 × 10⁻⁶ (Table 2). rs9601722 maps to a lncRNA (LOC105370284).

3.2.5 | Lethargy

SNPs at 12 loci had suggestive associations with lethargy (Supplementary Figure 3); however, only rs13413764 at 2q14.3 in...
patients treated with XELOX (OR = 1.8, 95% CI = 1.4-2.3, \( P = 4.5 \times 10^{-6} \)) was replicated in those receiving FOLFOX (OR = 1.5, 95% CI = 1.1-2.1, \( P = 9.2 \times 10^{-3} \)); pooled \( P = 7.5 \times 10^{-7} \) (Table 2). rs13413764 maps to an intergenic region.

### 3.2.6 Nausea

SNPs at 12 loci had suggestive associations with nausea (Supplementary Figure 3). However, only rs4600090 at 1p33 in patients treated with FOLFOX + cetuximab (OR = 4.0, 95% CI = 2.2-7.2, \( P = 5.9 \times 10^{-6} \)) was independently validated in those receiving FOLFOX (OR = 2.0, 95% CI = 1.1-4.0, \( P = 4.2 \times 10^{-2} \)); pooled \( P = 4.0 \times 10^{-6} \) (Table 2). rs4600090 was an eQTL for CMPK1, FOXE3 and PDZK1IP1 (Supplementary Figure 4).

### 3.2.7 Peripheral neuropathy, stomatitis, rash and neutropenic sepsis

SNPs at 15, 10, 8 and 4 loci had suggestive associations with peripheral neuropathy, stomatitis, skin rash and neutropenic sepsis, respectively, but no lead SNPs were independently validated.

### 3.3 MAGMA gene and pathway analyses

Gene and pathway analyses were performed considering approximately 17 000 genes and 8500 gene sets. Four genes were significantly associated with neutropenia (using a Bonferroni corrected threshold of \( P < 2.5 \times 10^{-6} \)). Of these, Maestro Heat-Like Repeat Family Member 5 (MROH5), found in patients treated with XELOX (\( P = 6.6 \times 10^{-7} \)), was independently validated in those receiving XELOX + cetuximab (\( P = 3.3 \times 10^{-2} \); pooled \( P = 3.7 \times 10^{-7} \) (Table 3; Supplementary Figure 5). Under a multivariate model accounting for sex and age, MROH5 remained significant in a pooled analysis of patients treated with XELOX and XELOX + cetuximab; pooled \( P = 1.0 \times 10^{-6} \).

MROH5 lies at 8q24.3, one of the 13 loci of suggestive association with neutropenia. The association of MROH5 with neutropenia appeared to be due to independent sets of SNPs in patients treated with XELOX (lead SNP rs76380775 OR = 4.8, 95% CI = 2.4-9.5, \( P = 1.4 \times 10^{-6} \)) as compared to those receiving XELOX + cetuximab (lead SNP rs12056882 OR = 4.4, 95% CI = 1.4-14, \( P = 1.0 \times 10^{-2} \); Supplementary Figure 6). Neither rs76380775 nor rs12056882 was associated with neutropenic sepsis or white blood cell count. rs12056882 was a sQTL for PTP4A3 (which lies 1.37 kb downstream of MROH5).

One gene was significantly associated with stomatitis, 3 genes (all mapping to 8q21.3) were associated with vomiting (Table 3) and 4, 8 and 3 gene sets were associated with any toxicity, lethargy and vomiting, respectively; however, all failed independent validation (Supplementary Tables 6 and 7).

### 3.4 Lack of confounding effect for rare DPYD variants

We have previously shown that two rare variants in DPYD (Asp949Val and IVS14+1G>A) were associated with a range of toxicities in COIN and COIN-B.\(^5\) Of the 1800 patients in our current GWASs, 22 carried Asp949Val and 17 carried IVS14+1G>A. Excluding these patients made no significant differences to the strengths of associations reported herein (Supplementary Table 8).

| Toxicity   | Treatment group | Gene | P-value  | Validation chemo P-value | Validation cetuximab status P-value | Pooled P-value |
|------------|-----------------|------|----------|--------------------------|-------------------------------------|----------------|
| Neutropenia| FOLFOX          | RPL17-C18orf32 | 8.9 \times 10^{-7} | .57 | .53 | — |
|            |                 | C18orf32  | 1.3 \times 10^{-6} | .56 | .51 | — |
|            |                 | RPL17     | 1.5 \times 10^{-6} | .56 | .52 | — |
|            | XELOX           | MROH5     | 6.6 \times 10^{-7} | 3.3 \times 10^{-2} | .09 | 3.7 \times 10^{-7} |
| Stomatitis | FOLFOX          | SCAF4 | 1.3 \times 10^{-6} | .07 | .61 | — |
| Vomiting   | XELOX           | LRRC69   | 1.2 \times 10^{-7} | .77 | .73 | — |
|            |                 | SLC26A7   | 4.3 \times 10^{-7} | .81 | .60 | — |
|            |                 | PIP4P2   | 9.7 \times 10^{-7} | .94 | .34 | — |

Notes: Significance was set at a Bonferroni-corrected significance threshold of \( P < 2.5 \times 10^{-6} \). Only MROH5 was significantly associated with neutropenia in patients treated with XELOX and was independently validated in patients receiving XELOX + cetuximab (\( P = 3.3 \times 10^{-2} \)), with a pooled \( P = 3.7 \times 10^{-7} \) (in bold) (and \( P = 5.8 \times 10^{-7} \) when also including the FOLFOX cohort).

Abbreviations: Validation cetuximab status, Validation in the COIN and COIN-B group with the alternative chemotherapy regimen but with the same cetuximab status; Validation chemo, validation in the COIN and COIN-B group with the same chemotherapy regimen but alternative cetuximab status.
3.5 Alternative model of toxicity

We considered an alternative model of toxicity comparing patients with grades 3 to 5 (ie, severe toxicity) to patients with grades 0 to 2 (no, mild or moderate toxicity) for all biomarkers identified herein (Supplementary Table 9). Five of the seven biomarkers remained nominally significant.

3.6 Evaluation of previously purported associations

A previous GWAS for toxicity to 5-FU or FOLFOX in patients with CRC identified two SNPs associated with mucositis, two with diarrhoea and three with haematological toxicities, albeit only at nominal significance. We failed to validate any of these SNPs in COIN and COIN-B (Supplementary Table 10), despite having adequate power.

4 DISCUSSION

MROH5 was identified from MAGMA gene analyses as associated with neutropenia at genome-wide significant levels in patients treated with XELOX and was independently validated in those receiving XELOX + cetuximab. Interestingly, this association appeared to be due to independent sets of SNPs in these two patient groups and rs12056882 was a sQTL for PTPA43 which lies adjacent to MROH5. MROH5 has been suggested to be both a pseudogene and a functional gene (with an unknown role) dependent upon the status of a SNP that introduces a premature termination codon. PTPA43 represents a strong causal candidate for neutropenia as treatment of mice with a PTPA43 derived peptide reduced endotoxemia-induced septic shock. PTPA43 expression has also been associated with poor prognosis in CRC possibly due to a role in metastasis and tumour invasion, and has been implicated in resistance to chemotherapy. Importantly, the strength of the relationship between SNPs and neutropenia suggests that they may have clinical utility as predictive biomarkers.

We also found a clear signal for rs13260246 associated with vomiting in patients treated with XELOX. However, this association was not validated in patients treated with XELOX + cetuximab, nor in those receiving FOLFOX, nor in patients treated with capcitabine plus bevacizumab from the QUASAR2 trial. Given that we had sufficient power to replicate the initial observation, these data suggest that rs13260246 is a false-positive although it remains possible that the association with vomiting is specific to those treated with XELOX alone. rs13260246 maps to, and is an eQTL for, SLC26A7, which functions as a Cl-/HCO3- exchanger and chloride channel, and is expressed in several tissues including the thyroid. Chemotherapy can cause thyroid dysfunction and response to treatment may be affected by pre-existing thyroid conditions. SLC26A7 is also expressed in parietal cells and genetic deletion results in decreased gastric acid secretion. Both thyroid and gastric dysfunction can cause vomiting.

Therefore, SLC26A7 represents a strong biological candidate for vomiting, but lacks genetic validation.

In total, we found SNPs at 139 loci with evidence for suggestive associations for any toxicity or individual toxicities and lead SNPs at five of these were validated at nominally significant levels. However, if we applied a more stringent correction for 139 validation tests, none of the five would have passed the adjusted significance threshold. Further validation of these biomarkers in independent cohorts is therefore necessary before they could be applied in clinical practice. rs6030266 was associated with diarrhoea and identified in patients treated with cetuximab. It maps to intron eight of PTPRT, a tumour suppressor gene that functions as part of the JAK/STAT pathway.

We also found a clear signal for rs13260246 associated with vomiting. Further analyses of these SNPs in COIN and COIN-B (Supplementary Table 10), despite having adequate power.

ACKNOWLEDGEMENTS

We thank Hywel Williams for helpful advice and the patients and their families who participated and gave their consent for this research, and the investigators throughout the UK who submitted samples for assessment. This work was supported by Cardiff University School of Medicine (to K.W.), Tenovus Cancer Care (to J.P.C. and C.W.), KFSHRC (to N.A.A.) and Cancer Research UK (grant number C1298/ A8362 to R.S.H.). The COIN and COIN-B trials were funded by Cancer Research UK, the Medical Research Council and an unrestricted educational grant from Merck-Serono and were conducted with the support of the National Institute of Health Research Cancer Research Network. None of the sponsors played a role in the study design; the collection, analysis and interpretation of data; the writing of the report; and the decision to submit the paper for publication.

CONFLICT OF INTEREST

T.S.M. received research funding from Merck KgAa (manufacturer of cetuximab) for unrelated research. The original COIN trial received
funding from Merck KgAa as well as Cancer Research UK. T.S.M. received honorarium and travel support from Merck KgAa. D.K. is a director of Oxford Cancer Biomarkers. All other authors have declared no potential conflicts of interest.

ETHICS STATEMENT

Patients were recruited from the MRC clinical trials COIN (ISRCTN27286448) and COIN-B (ISRCTN38375668) and all gave fully informed consent for bowel cancer research (approved by REC 04/MRE06/60).

DATA AVAILABILITY STATEMENT

The GWAS summary statistics are available through the NHGRI-EBI GWAS Catalog under study accession numbers GCST90017191 - GCST90018000. Further details and other data that support the findings of this study are available from the corresponding author upon request.

ORCID

Jeremy P. Cheadle https://orcid.org/0000-0001-9453-8458

REFERENCES

1. Schmoll HJ, Van Cutsem E, Stein A, et al. Esmo consensus guidelines for management of patients with colon and rectal cancer: A personalized approach to clinical decision making. Ann Oncol. 2012;23:2479-2516.
2. Stein A, Arnold D. Oxaliplatin: a review of approved uses. Expert Opin Pharmacother. 2012;13:125-137.
3. Duceux M, Benniala J, Hebbah M, et al. Efficacy and safety findings from a randomized phase III study of capecitabine (X) + oxaliplatin (O) (XELOX) vs. infusional 5-FU/LV + O (FOLFFOX-6) for metastatic colorectal cancer (MCRC). J Clin Oncol. 2007;25:4029-4029.
4. Guo Y, Xiong BH, Zhang T, Cheng Y, Ma L. XELOX vs. infusional 5-FU/LV in metastatic colorectal cancer: an updated meta-analysis. Cancer Invest. 2016;34:94-104.
5. Petrelli F, Boronovk K, Barni S. The predictive role of skin rash with cetuximab and panitumumab in colorectal cancer patients: a systematic review and meta-analysis of published trials. Target Oncol. 2013;8:173-181.
6. Andreyev HJN, Davidson SE, Gillespie C, Allum WH, Swarbrick E. Practice guidance on the management of acute and chronic gastrointestinal problems arising as a result of treatment for cancer. Gut. 2012;61:179-192.
7. Blumenthal GM, Gong Y, Kehl K, et al. Analysis of time-to-treatment discontinuation of targeted therapy, immunotherapy, and chemotherapy in clinical trials of patients with non-small-cell lung cancer. Ann Oncol. 2019:30:830-838.
8. Koedoot CG, De Haan RJ, Stiggelbout AM, et al. Palliative chemotherapy or best supportive care? A prospective study explaining patients’ treatment preference and choice. Br J Cancer. 2003;89:2219-2226.
9. Huitema ADR, Spaander M, Mathôt RAA, et al. Relationship between exposure and toxicity in high-dose chemotherapy with cyclophosphamide, thiopeta and carboplatin. Ann Oncol. 2002;13:374-384.
10. Braun MS, Seymour MT. Balancing the efficacy and toxicity of chemotherapy in colorectal cancer. Ther Adv Med Oncol. 2011;3:43-52.
11. Schwab M, Zanger UM, Marx C, et al. Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-FU toxicity study group. J Clin Oncol. 2008;26:2131-2138.
12. Henricks LM, Lunenburg CATC, de Man FM, et al. DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis. Lancet Oncol. 2018;19:1459-1467.
13. Gonzalez FJ, Fernandez-Salgueiro P. Diagnostic analysis, clinical importance and molecular basis of dihydropyrimidinase dehydrogenase deficiency. Trends Pharmacol Sci. 1995;16:325-327.
14. Wei X, McLeod HL, McMurrugh J, Gonzalez FJ, Fernandez-Salgueiro P. Molecular basis of the human dihydropyrimidinase dehydrogenase deficiency and 5-fluorouracil toxicity. J Clin Invest. 1996;98:610-615.
15. Madi A, Fisher D, Maughan TS, et al. Pharmacogenetic analyses of 2183 patients with advanced colorectal cancer: potential role for common dihydropyrimidinate dehydrogenase variants in toxicity to chemotherapy. Eur J Cancer. 2018;102:31-39.
16. Maughan TS, Adams RA, Smith CG, et al. Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet. 2011;377:2103-2114.
17. Adams RA, Meade AM, Seymour MT, et al. Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet Oncol. 2011;12:642-653.
18. Wasan H, Meade AM, Adams R, et al. Intermittent chemotherapy plus either intermittent or continuous cetuximab for first-line treatment of patients with KRAS wild-type advanced colorectal cancer (COIN-B): a randomised phase 2 trial. Lancet Oncol. 2014;15:631-639.
19. Moore CM, Jacobson SA, Fingerlin TE. Power and sample size calculations for genetic association studies in the presence of genetic model misspecification. Hum Hered. 2019;84:256-271. https://doi.org/10.1159/000508558.
20. Al-Tasser NA, Whiffin N, Hosking FJ, et al. A new GWAS and meta-analysis with 1000Genomes imputation identifies novel risk variants for colorectal cancer. Sci Rep. 2015;5:10442.
21. Purcell S, Neale B, Todd-Brown K, et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet. 2007;81:559-575.
22. Turner SD, qmap: an R package for visualizing GWAS results using Q-Q and manhattan plots. J Open Source Softw. 2018;3:731.
23. de Leeuw CA, Moolij JM, Heskes T, Posthuma D. MAGMA: general-ized gene-set analysis of GWAS data. PLoS Comput Biol. 2015;11:e1004219.
24. Kerr RS, Love S, Segelov E, et al. Adjuvant capecitabine plus bevacizumab versus capecitabine alone in patients with colorectal cancer (QUASAR 2): an open-label, randomised phase 3 trial. Lancet Oncol. 2016;17:1543-1557.
25. Khachat G, Yang W-Y, Lindstrom S, et al. Integrating functional data to prioritize causal variants in statistical fine-mapping studies. PLoS Genet. 2014;10:e1004722.
26. Fernandez-Rozadilla C, Casier JB, Moreno V, et al. Pharmacogenomics in colorectal cancer: a genome-wide association study to predict toxicity after 5-fluorouracil or FOLFOX administration. Pharmacogenomics J. 2013;13:209-217.
27. Tang X, Woodward T, Amar S, et al. PTP4A3 peptide PIMAP39 modulates TNF-alpha levels and endotoxic shock. J Innate Immun. 2009;2:43-55.
28. Zimmerman MW, Homances G, Lazo JS. Targeted deletion of the metastasis-associated phosphatase Ptp4a3 (PRL3) suppresses murine colon cancer. PLoS One. 2013;8:e85800.
29. Saha S, Bardelli A, Buckhaults P, et al. A phosphatase associated with metastasis of colorectal cancer. Science. 2001;294:1343-1346.
30. Csoboz B, Gombos I, Tatali E, et al. Chemotherapy induced PRL3 expression promotes cancer growth via plasma membrane remodeling and specific alterations of caveolae-associated signaling. Cell Commun Signal. 2018:16:51.
31. den Hollander P, Rawls K, Tsimelzon A, et al. Phosphatase PTP4A3 promotes triple-negative breast cancer growth and predicts poor patient survival. Cancer Res. 2016;76:1942-1953.
32. Kim KH, Shcheynikov N, Wang Y, Muallem S. SLC26A7 is a Cl⁻ channel regulated by intracellular pH. J Biol Chem. 2005;280:6463-6470.
33. Fujiwara Y, Chayahara N, Mukohara T, et al. Hypothyroidism in patients with colorectal carcinoma treated with fluoropyrimidines. Oncol Rep. 2013;30:1802-1806.
34. Andreyev HJN, Lalji A, Mohammed K, et al. The FOCCUS study: a prospective evaluation of the frequency, severity and treatable causes of gastrointestinal symptoms during and after chemotherapy. Support Care Cancer. 2021;29:1443-1453.
35. Hartmann PA-CK. Thyroid disorders in the oncology patient. J Adv Pract Oncol. 2015;6:99.
36. Xu J, Song P, Nakamura S, et al. Deletion of the chloride transporter Slc26a7 causes distal renal tubular acidosis and impairs gastric acid secretion. J Biol Chem. 2009;284:29470-29479.
37. Petrovic S, Ju X, Barone S, et al. Identification of a basolateral Cl⁻/HCO₃⁻ exchanger specific to gastric parietal cells. Am J Physiol Liver Physiol. 2003;284:G1093-G1103.
38. Sweet C, Sharma A, Lipscomb G. Recurrent nausea, vomiting and abdominal pain due to hypothyroidism. BMJ Case Rep. 2010;10:2010bcr1120092461.
39. Raufman JP, Collins SM, Pandol SJ, et al. Reliability of symptoms in assessing control of gastric acid secretion in patients with Zollinger-Ellison syndrome. Gastroenterology. 1983;84:108-113.
40. Hsu HC, Lapke N, Chen SJ, et al. PTPRT and PTPRD deleterious mutations and deletion predict bevacizumab resistance in metastatic colorectal cancer patients. Cancers (Basel). 2018;10:314.
41. Takada K, Zhu D, Bird GH, et al. Targeted disruption of the BCL9/β-catenin complex inhibits oncogenic Wnt signaling. Sci Transl Med. 2012;4:148ra117.
42. Yasuno H, Kurasawa M, Yanagisawa M, Sato Y, Harada N, Mori K. Predictive markers of capecitabine sensitivity identified from the expression profile of pyrimidine nucleoside-metabolizing enzymes. Oncol Rep. 2013;29:451-458.
43. Fredrikson M, Hursti TJ, Steineck G, Fürst CJ, Börjesson S, Peterson C. Delayed chemotherapy-induced nausea is augmented by high levels of endogenous noradrenaline. Br J Cancer. 1994;70:642-645.

SUPPORTING INFORMATION
Additional supporting information may be found online in the Supporting Information section at the end of this article.

How to cite this article: Watts K, Wills C, Madi A, et al. Genome-wide association studies of toxicity to oxaliplatin and fluoropyrimidine chemotherapy with or without cetuximab in 1800 patients with advanced colorectal cancer. Int. J. Cancer. 2021;1-10. https://doi.org/10.1002/ijc.33739